ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS

Date de début de l'étude : 1 juin 1996

DISEASE CHARACTERISTICS: Idiopathic myelofibrosis (IMF) with at least 1 poor prognosis characteristic, including but not limited to: Hemoglobin less than 10 g/dL Platelet count less than 100,000/mm^3 Hepatomegaly (i.e., palpable liver edge 5 cm below costal margin) Clinical requirement for splenectomy Other myeloproliferative disorders in an IMF like myelofibrotic state eligible No evidence of leukemic progression, e.g.: Greater than 15% peripheral blood blasts Fever or bone pain of unknown origin Rapidly progressing splenomegaly No other causes for myelofibrosis, such as: Collagen vascular disorder Lymphoma Granulomatous infection Metastatic carcinoma Hairy cell leukemia Myelodysplastic syndrome No active central nervous system disease One of the following donor/patient pairings is required: Donor status: Genotypic or phenotypic HLA-matched relative Maximum patient age of 65 One antigen HLA-mismatched relative, HLA-matched unrelated donor, or one antigen HLA-mismatched unrelated donor Maximum patient age of 55 Transplant on this protocol allowed for patients registered on protocol FHCRC-1106.00 PATIENT CHARACTERISTICS: Age: 65 and under Performance status: Not specified Hematopoietic: See Disease Characteristics Hepatic: Bilirubin no greater than 2 times normal SGPT no greater than 4 times normal Renal: Creatinine no greater than two times normal OR Creatinine clearance at least 50% Cardiovascular: Ejection fraction at least 50% Cardiac evaluation required if signs or symptoms of coronary artery disease or congestive heart failure Other: HIV negative No active infection Patients excluded from this protocol are referred to protocol FHCRC-179.05 PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified